Accéder au contenu
MilliporeSigma
  • Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.

Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.

Journal of neuroscience methods (2015-02-15)
Sucharita S Somkuwar, Kathleen M Kantak, Linda P Dwoskin
RÉSUMÉ

Attention deficit hyperactivity disorder (ADHD) is associated with hypofunctional medial prefrontal cortex (mPFC) and orbitofrontal cortex (OFC). Methylphenidate (MPH) remediates ADHD, in part, by inhibiting the norepinephrine transporter (NET). MPH also reduces ADHD-like symptoms in spontaneously hypertensive rats (SHRs), a model of ADHD. However, effects of chronic MPH treatment on NET function in mPFC and OFC in SHR have not been reported. In the current study, long-term effects of repeated treatment with a therapeutically relevant oral dose of MPH during adolescence on NET function in subregions of mPFC (cingulate gyrus, prelimbic cortex and infralimbic cortex) and in the OFC of adult SHR, Wistar-Kyoto (WKY, inbred control) and Wistar (WIS, outbred control) rats were determined using in vivo voltammetry. Following local ejection of norepinephrine (NE), uptake rate was determined as peak amplitude (Amax)× first-order rate constant (k-1). In mPFC subregions, no strain or treatment effects were found in NE uptake rate. In OFC, NE uptake rate in vehicle-treated adult SHR was greater than in adult WKY and WIS administered vehicle. MPH treatment during adolescence normalized NE uptake rate in OFC in SHR. Thus, the current study implicates increased NET function in OFC as an underlying mechanism for reduced noradrenergic transmission in OFC, and consequently, the behavioral deficits associated with ADHD. MPH treatment during adolescence normalized NET function in OFC in adulthood, suggesting that the therapeutic action of MPH persists long after treatment cessation and may contribute to lasting reductions in deficits associated with ADHD.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Chlorure de sodium, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
Chlorure de sodium solution, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
Chlorure de sodium, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
Chlorure de sodium solution, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
L-acide ascorbique, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L-acide ascorbique, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
Chlorure de sodium, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
L-acide ascorbique, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L-acide ascorbique, 99%
Sigma-Aldrich
Acide perchlorique, 70%, 99.999% trace metals basis
SAFC
Chlorure de sodium solution, 5 M
Sigma-Aldrich
L-acide ascorbique, reagent grade, crystalline
Sigma-Aldrich
Chlorure de sodium, meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%
Sigma-Aldrich
Chlorure de sodium solution, BioUltra, for molecular biology, ~5 M in H2O
Sigma-Aldrich
Chlorure de sodium solution, 5 M
Sigma-Aldrich
Chlorure de sodium, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
L-acide ascorbique, ACS reagent, ≥99%
Sigma-Aldrich
Chlorure de sodium, 99.999% trace metals basis
Sigma-Aldrich
Urethane, ≥99%
Sigma-Aldrich
L-acide ascorbique, reagent grade
Sigma-Aldrich
L-acide ascorbique, meets USP testing specifications
Sigma-Aldrich
L-acide ascorbique, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
L-acide ascorbique, FCC, FG